Report of the 15th follow-up survey of primary liver cancer

被引:127
作者
Ikai, I [1 ]
Itai, Y [1 ]
Okita, K [1 ]
Omata, M [1 ]
Kojiro, M [1 ]
Kobayashi, K [1 ]
Nakanuma, Y [1 ]
Futagawa, S [1 ]
Makuuchi, M [1 ]
Yamaoka, Y [1 ]
机构
[1] Liver Canc Study Grp Japan, Sakyo Ku, Kyoto, Japan
关键词
follow-up survey; primary liver cancer; hepatocellular carcinoma; intrahepatic cholangiocarcinorna; cumulative survival rate;
D O I
10.1016/j.hepres.2003.08.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the 15th Nationwide follow-up survey of primary liver cancer, 18,843 newly registered patients (1998-1999) and 18,405 follow-up patients from 791 hospitals in Japan were analyzed. Of the newly registered patients, approximately 95% were patients with hepatocellular carcinoma (HCC) and 3.3% had intrahepatic cholangiocarcinoma (ICC). The patients were assessed using 194 items that were related to epidemiological and clinicopathological factors, diagnosis, and treatment. Furthermore, the survival rates of all of the newly registered patients in the 10th-15th follow-up survey were calculated for each histological type, background factor(s) and treatment, respectively. In patients with hepatocellular carcinoma, the survival rates of patients who underwent hepatectomy, ethanol injection therapy, microwave coagulation therapy, or transcatheter arterial embolization were calculated by tumor size, tumor number, and clinical stage. This follow-up survey will be helpful to assess the progress of research and medical practice in the treatment of primary liver cancer. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 9 条
[1]   Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan [J].
Arii, S ;
Yamaoka, Y ;
Futagawa, S ;
Inoue, K ;
Kobayashi, K ;
Kojiro, M ;
Makuuchi, M ;
Nakamura, Y ;
Okita, K ;
Yamada, R .
HEPATOLOGY, 2000, 32 (06) :1224-1229
[2]  
*LIV STUD GROUP JA, 1997, CLASS PRIM LIV CANC
[3]  
Liver Cancer Study Group of Japan, 1990, Ann Surg, V211, P277
[4]  
ROBE T, 1992, PRIMARY LIVER CANC J
[5]  
*SAS I INC, 1992, P229 SAS I INC, P433
[6]  
*SAS I INC, 1985, SAS US GUID BAS VERS, P861
[7]  
TOBE T, 1994, CANCER-AM CANCER SOC, V74, P2772, DOI 10.1002/1097-0142(19941115)74:10<2772::AID-CNCR2820741006>3.0.CO
[8]  
2-V
[9]  
TOBE T, 1987, CANCER-AM CANCER SOC, V60, P1400